Cargando…
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
OBJECTIVE: Inhibiting sodium–glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and SGLT2 on multiple parameters. RESEARCH DESIGN AND M...
Autores principales: | Posch, Maximilian G., Walther, Niklas, Ferrannini, Ele, Powell, David R., Banks, Phillip, Wason, Suman, Dahmen, Raphael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472498/ https://www.ncbi.nlm.nih.gov/pubmed/35817022 http://dx.doi.org/10.2337/dc21-2166 |
Ejemplares similares
-
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
por: Bramlage, Peter, et al.
Publicado: (2020) -
OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019) -
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022) -
Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020) -
Effect of vitamin D(3) supplementation on glycated hemoglobin (HbA1c), fructosamine, serum lipids, and body mass index: a randomized, double-blinded, placebo-controlled trial among healthy immigrants living in Norway
por: Madar, Ahmed A, et al.
Publicado: (2014)